Veracyte Inc. (NASDAQ:VCYT) was down 1% during trading on Friday . The stock traded as low as $4.85 and last traded at $4.99, with a volume of 70,804 shares traded. The stock had previously closed at $5.04.

Several equities research analysts have recently commented on VCYT shares. Cantor Fitzgerald reissued a “buy” rating and set a $13.00 price target on shares of Veracyte in a research note on Sunday, March 13th. Leerink Swann reaffirmed a “buy” rating on shares of Veracyte in a research note on Thursday, June 23rd. BTIG Research reaffirmed a “buy” rating and issued a $10.00 target price on shares of Veracyte in a research note on Monday, June 13th. Finally, Zacks Investment Research lowered Veracyte from a “buy” rating to a “hold” rating in a research note on Friday, March 18th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $9.75.

The firm’s 50-day moving average is $5.22 and its 200 day moving average is $5.69. The firm’s market capitalization is $139.01 million.

Veracyte (NASDAQ:VCYT) last issued its earnings results on Thursday, May 5th. The company reported ($0.36) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.01. The company had revenue of $13.55 million for the quarter, compared to analysts’ expectations of $13.08 million. During the same period last year, the firm earned ($0.34) EPS. The business’s quarterly revenue was up 21.0% compared to the same quarter last year. Analysts anticipate that Veracyte Inc. will post ($1.31) earnings per share for the current fiscal year.

In other news, CEO Bonnie H. Anderson acquired 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 1st. The stock was purchased at an average price of $5.46 per share, with a total value of $27,300.00. Following the purchase, the chief executive officer now owns 2,500 shares of the company’s stock, valued at approximately $13,650. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Veracyte, Inc is a molecular diagnostics company. The Company is engaged in the field of molecular cytology providing genomic solutions to resolve diagnostic ambiguity and enable physicians to make treatment decisions at an early stage in patient care. It targets diseases in which a large number of patients undergo invasive diagnostic procedures that could be avoided with a diagnosis from a cytology sample.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.